Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026)

Neurogene posted quarterly Depreciation & Amortization (CF) of $847000.0 for Q1 2026, up 13.08% year-on-year from $749000.0 in Q1 2025, and up 15.55% on a QoQ basis from $733000.0 in Q4 2025.

Neurogene (NGNE) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $847000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 13.08% year-over-year to $847000.0; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 0.98% YoY), and the FY2025 full-year result was $3.0 million, down 6.25% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $847000.0, up from $733000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.0 million in Q4 2022 and bottomed at $323000.0 in Q3 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $800000.0 (2023), against an average of $797411.8.
  • The widest annual swing landed in 2022, when Depreciation & Amortization (CF) surged 413.59%; it then tumbled 59.21% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.0 million in 2022, then sank by 59.21% to $817000.0 in 2023, then fell by 2.08% to $800000.0 in 2024, then fell by 8.38% to $733000.0 in 2025, then climbed by 15.55% to $847000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $847000.0 (Q1 2026), $733000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 1,395.22
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 13.55 Mn
10 Neurogene 632.14 Mn 632.14 Mn - 847,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 847,000.00
Mar 31, 2026 847,000.00
Dec 31, 2025 733,000.00
Dec 31, 2025 733,000.00
Sep 30, 2025 800,000.00
Sep 30, 2025 800,000.00
Jun 30, 2025 800,000.00
Jun 30, 2025 800,000.00
Mar 31, 2025 749,000.00
Mar 31, 2025 749,000.00
Dec 31, 2024 800,000.00
Dec 31, 2024 800,000.00
Sep 30, 2024 800,000.00
Sep 30, 2024 800,000.00
Jun 30, 2024 800,000.00
Jun 30, 2024 800,000.00
Mar 31, 2024 814,000.00
Mar 31, 2024 814,000.00
Dec 31, 2023 817,000.00
Dec 31, 2023 817,000.00
Sep 30, 2023 800,000.00
Sep 30, 2023 800,000.00
Jun 30, 2023 800,000.00
Jun 30, 2023 800,000.00
Mar 31, 2023 800,000.00
Mar 31, 2023 800,000.00
Dec 31, 2022 2.00 Mn
Dec 31, 2022 2.00 Mn
Sep 30, 2022 323,000.00
Sep 30, 2022 323,000.00
Jun 30, 2022 459,000.00
Jun 30, 2022 459,000.00
Mar 31, 2022 411,000.00
Mar 31, 2022 411,000.00
Dec 31, 2021 390,000.00
Dec 31, 2021 390,000.00
Sep 30, 2021 356,000.00
Sep 30, 2021 356,000.00
Jun 30, 2021 313,000.00
Jun 30, 2021 313,000.00
Mar 31, 2021 247,000.00
Mar 31, 2021 247,000.00
Dec 31, 2020 207,000.00
Dec 31, 2020 207,000.00
Sep 30, 2020 188,000.00
Sep 30, 2020 188,000.00
Jun 30, 2020 219,000.00
Jun 30, 2020 219,000.00
Mar 31, 2020 171,000.00
Mar 31, 2020 171,000.00
Dec 31, 2019 160,000.00
Dec 31, 2019 160,000.00
Sep 30, 2019 98,000.00
Sep 30, 2019 98,000.00
Jun 30, 2019 41,000.00
Jun 30, 2019 41,000.00
Mar 31, 2019 41,000.00
Mar 31, 2019 41,000.00
Dec 31, 2014 20,456.00
Dec 31, 2014 20,456.00
Sep 30, 2014 25,314.00
Sep 30, 2014 25,314.00
Jun 30, 2014 71,938.00
Jun 30, 2014 71,938.00
Mar 31, 2014 18,238.00
Mar 31, 2014 18,238.00
Dec 31, 2013 14,373.00
Dec 31, 2013 14,373.00
Sep 30, 2013 14,821.00
Sep 30, 2013 14,821.00
Jun 30, 2013 15,592.00
Jun 30, 2013 15,592.00
Mar 31, 2013 14,785.00
Mar 31, 2013 14,785.00